{
  "id": 7281756,
  "title": "Apollo in talks to acquire J&J’s DePuy Synthes for around $20bn",
  "url": "https://urgent.news/2026/09/14/apollo-in-talks-to-acquire-j-js-depuy-synthes-for-around-20bn",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-14T08:40:02.000Z",
  "source": {
    "name": "Private Equity Wire",
    "slug": "private-equity-wire",
    "url": "https://www.privateequitywire.co.uk/apollo-in-talks-to-acquire-jjs-depuy-synthes-for-around-20bn/"
  },
  "original_language": "en",
  "account": "Apollo Global Management is reportedly engaged in talks to acquire Johnson & Johnson's orthopaedics business, DePuy Synthes, for nearly $20 billion, according to Bloomberg citing unnamed sources. The private equity firm is among several potential buyers for the unit, which J&J announced its intention to separate last year. Talks with Apollo could be finalized within weeks, though the discussions are still ongoing and may not result in a deal. J&J may also consider alternative options, such as selling the business to a different bidder or spinning it off as an independent company. No comment has been made by representatives from either Apollo or J&J. In October 2025, J&J announced its plans to separate its orthopaedics operations, which CFO Joseph Wolk stated in July would focus on maximizing shareholder value and positioning DePuy Synthes for long-term growth. The division generates $9.3 billion in annual revenue, producing medical devices for orthopaedic procedures such as hip and knee replacements.",
  "summary": "TOP STORY: Apollo Global Management is in discussions to acquire Johnson & Johnson’s DePuy Synthes orthopaedics business in a deal that could value the unit at close to $20bn, according to a report by Bloomberg citing unnamed people familiar with the matter.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}